GLPwatch
Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
Med · 2025
Last updated 2026-05-28In a trial with 731 participants, the drug tirzepatide improved quality of life and reduced worsening heart failure events by 38% in people with heart failure with preserved ejection fraction (HFpEF) and obesity. The drug works by targeting both GIP and GLP-1 receptors.
AI summary of the abstract below.
| Journal | Med, 2025 |
|---|---|
| Citations | 1 |
| Molecules | tirzepatide |
| Conditions studied | Heart Failure |
Abstract
The SUMMIT trial showed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with HF with preserved ejection fraction (HFpEF) and obesity. Some concerns, however, remain.
Verbatim abstract via PubMed 39954669 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.